About: Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.16 (-4.22%)
NKTX NASDAQ Nkarta Inc
Nkarta Inc share price
NKTX price activity
Last Price
$2.160
Change (24hr)
-0.10 USD (-4.22%)
Volume
133.76K
Volume (4w avg)
-
Open
$2.25
Day Range
$2.16 - $2.25
Previous Close
$2.25
Last Trade
12 Oct, 2:44 pm GMT+0
Delayed
12 Oct, 2:44 pm GMT+0
NKTX price performance
Delayed
12 Oct, 2:44 pm GMT+0
NKTX Market Signals